Gordon, K, R B Warren, A B Gottlieb, A Blauvelt, D Tha?i, Y Poulin, M Boehnlein, F Brock, C Arendt, and K Reich. “Durable Efficacy of Certolizumab Pegol Dosed at 400 Mg Every Two Weeks Over 128 Weeks in Patients With Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT)”. SKIN The Journal of Cutaneous Medicine 4, no. 5 (September 2, 2020): s45. Accessed July 12, 2024. https://jofskin.org/index.php/skin/article/view/994.